ORIGINAL ARTICLE |
|
Year : 2014 | Volume
: 1
| Issue : 2 | Page : 99-104 |
|
Single dose metformin kinetics after co-administration of nisha-amalaki powder or mamejwa ghanavati, ayurvedic anti-diabetic formulations: A randomized crossover study in healthy volunteers
Amrutesh Puranik1, Nutan Nabar2, Jayashree Joshi2, Ashok Amonkar2, Sanjiv Shah2, Sasikumar Menon3, Rama Vaidya2, Ashok D.B. Vaidya2
1 Department of Reverse Pharmacology, Medical Research Center, Kasturba Health Society, ICMR Advanced Centre of Reverse Pharmacology in Traditional Medicine Mumbai, Maharashtra; Department of Integrative Biology and Physiology, School of Medicine, University of Minnesota, MN 55455, USA 2 Department of Reverse Pharmacology, Medical Research Center, Kasturba Health Society, ICMR Advanced Centre of Reverse Pharmacology in Traditional Medicine Mumbai, Maharashtra, India 3 Therapeutic Drug Monitoring Laboratory, Sion Koliwada, Sion East, Mumbai, Maharashtra, India
Correspondence Address:
 Source of Support: CSIR NMITLI for funding the project at our center,, Conflict of Interest: None  | Check |
DOI: 10.4103/2347-9906.134423
|
|
Objective: The aim was to study herb-drug interaction of two ayurvedic formulations - DMFN01 (Nisha-Amalaki) powder and DMFN02 (Mamejava) ghanavati with metformin at a single dose in healthy volunteers. Materials and Methods: This was an open-labelled, single dose, crossover, and randomized volunteer study. Healthy volunteers were studied in two groups (6/group). Volunteers were randomized to oral metformin (500 mg single dose) alone or with concurrent DMFN01 (10 g), or DMFN02 (750 mg). Venous blood samples were collected at different time points from 0 to 24 h. Plasma metformin concentrations were measured by high performance liquid chromatography coupled with an ultraviolet detector. Results: Simultaneous administration of DMFN01 with metformin showed a reduction in the mean area under the curve (AUC [0-24 h]) of metformin by 51% (P < 0.002) when compared with metformin alone. However, co-administration of DMFN02 did not show any significant difference in the mean AUC of metformin (P = 0.645). One volunteer had a reduction of 41% in AUC of metformin with DMFN 02. Conclusions: These data raise relevant questions on therapeutic control of hyperglycemia when DMFN01 choorna is given concurrently with metformin. Based on known absorption pattern of metformin an interval of 2 h between the oral doses of metformin and ayurvedic formulations would be advisable to avoid interactions. In reverse pharmacological studies, at an early stage, such interaction studies are desirable. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|